<DOC>
	<DOCNO>NCT02462603</DOCNO>
	<brief_summary>Open-label study 30-day run-in phase adaptive design component include subject deem appropriate investigator .</brief_summary>
	<brief_title>Safety Biomarker Study EPI-589 Parkinson 's Disease</brief_title>
	<detailed_description>This within-subject , control open-label study seek determine EPI-589 alter biochemical signature PD assess peripheral blood brain image biomarkers . Data also collect disease-relevant clinical measure collect .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Hoehn Yahr stage ≤ 2.5 Ambulatory without assistance Agreement use contraception within reproductive year Willingness ability comply study procedure Stable regimen dietary supplement 30 day prior enrollment Abstention use investigative nonapproved drug duration trial For Idiopathic Subjects A diagnosis early idiopathic PD confirm presence bradykinesia plus one following symptom : rigidity rest tremor ; abnormal DaTscan consistent dopaminergic deficit Must yet require symptomatic medication PD expect require treatment end study Age 40 75 year Within 5 year diagnosis Parkinson 's disease For Genetic Subtype Subjects A confirmed diagnosis PD plus genetic diagnosis consistent PD , specifically PINK1 , parkin , LARK2 genetic subtype Age 21 75 year Stable medication regimen PD drug 30 day ( except 60 day rasagiline ) prior enrollment Allergy EPI589 component EPI589 tablet formulation Use antioxidant supplement , specifically vitamins E C beyond recommended daily allowance Other Parkinsonian disorder MoCA score &lt; 24 Revised Hamilton Rating Scale Depression ≥ 11 Parkinsonism due drug toxins Diagnosis clinically significant neurologic disease confound assessment effect study drug disease progression Malignancy within past two year Pregnant plan become pregnant breast feed History stroke History brain surgery Hepatic insufficiency liver function test ( LFTs ) &gt; 3 time upper limit normal Renal insufficiency define creatinine &gt; 1.5 time normal End stage cardiac failure Participation within past 3 month duration study trial device , drug therapy PD For Idiopathic Subjects Use MAO inhibitor , amantadine drug prescribe core symptom Parkinson 's disease idiopathic subject Use nortriptyline fluvoxamine 60 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>PD</keyword>
	<keyword>EPI-589</keyword>
	<keyword>EPI589</keyword>
</DOC>